Story

Moderna Stock Slides as Investors Reassess Valuation After Cancer Vaccine Rally

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20262 min read
Moderna Stock Slides as Investors Reassess Valuation After Cancer Vaccine Rally
Text size
Background

Moderna (MRNA) shares fell sharply in morning trading, declining 5.6% to $149.87 as investors took profits following a significant rally last week. The sell-off represents a broader reassessment of the company's valuation after initial enthusiasm for its promising cancer vaccine trial results.

Valuation Concerns Follow Surge

The stock's decline comes after a rally of over 14% on Tuesday, which was fueled by positive analyst actions. However, the primary headwind for the stock is a disconnect between its current market price and Wall Street's fundamental valuations.

Even with recent upgrades, analyst price targets remain well below current trading levels, suggesting concerns that the stock has run up too far, too fast. Key analyst targets include:

  • Barclays: Raised its price target to $125.
  • Wolfe Research: Upgraded the stock to Peerperform from Underperform.
  • JPMorgan: Holds a revised price target of $77.

Fundamental and Market Headwinds

Sample IUX Markets – In-articleAd

Underlying the valuation debate are Moderna's current financials. The company is not yet profitable, reporting a net loss of $782 million on revenue of just $145 million in its most recent quarter. Analysts note that meaningful revenue from its cancer vaccine, intismeran, is likely still years away due to the complexities of commercialization.

A lack of broad market support is also contributing to the pullback. Major indices like the S&P 500 and Nasdaq were trading flat, providing no tailwind for growth stocks. Furthermore, the wider biotech sector, as measured by the SPDR S&P Biotech ETF (XBI), has also been correcting after surging on the initial news from Moderna and its partner, Merck.

Awaiting the Next Catalyst

Today's decline reflects the natural tension between a significant clinical breakthrough and the long-term commercial realities. The stock's volatile 52-week range, from a low of $22.28 to a high of $176.66, highlights its sensitivity to news flow.

Investors now appear to be reducing exposure while awaiting more concrete developments. The market is looking for the next major catalyst, which would include the presentation of comprehensive efficacy and overall survival data at a medical conference, followed by eventual regulatory submissions.

Read next

More on Stocks
Back to latest news

LATEST